Chinese expert consensus for treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan

Expert group on the treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan

PDF(29210 KB)
Chinese Journal of Nephrology
Chinese Journal of Nephrology ›› 2022, Vol. 38 ›› Issue (7) : 644-652. DOI: 10.3760/cma.j.cn441217-20220110-00093
Expert Consensus

Chinese expert consensus for treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 38(7): 644-652. DOI: 10.3760/cma.j.cn441217-20220110-00093.

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(29210 KB)

Accesses

Citation

Detail
Sections
Recommended

Copyright© by the Editorial Board of Chinese Journal of Nephrology, Chinese Medical Association and the First Affiliated Hospital of Sun Yat-sen University (Guangzhou) Journal Co., Ltd

Address: Floor 2, Longzhu building, No. 5, Zhusigang Second Road, Yuexiu District, Guangzhou (510080) Tel：(020)87331532　Email：cmaszb@mail.sysu.edu.cn

This system is designed and developed by Beijing magtec Technology Development Co., Ltd. with technical support: support@magtech.com.cn

粤ICP备10090623号

/

〈 〉